Skip to main content

Advertisement

SpringerLink
Log in

Insights into natriuretic peptides in heart failure: An update

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate [cGMP]), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pankow K, Wang Y, Gembardt F, et al.: Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007, 101:875–882.

    Article  PubMed  CAS  Google Scholar 

  2. Brandt I, Lambeir AM, Ketelslegers JM, et al.: Dipeptidylpeptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006, 52:82–87.

    Article  PubMed  CAS  Google Scholar 

  3. Huntley BK, Sandberg SM, Noser JA, et al.: BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol 2006, 209:943–949.

    Article  PubMed  CAS  Google Scholar 

  4. Stevens TL, Borgeson DD, Luchner A, et al.: A modified model of tachycardia-induced cardiomyopathy: insights into humoral and renal adaptations. In Pathophysiology of Tachycardia-Induced Heart Failure. Edited by Spinale FG. New York: Futura Publishing; 1996:133–151.

    Google Scholar 

  5. Charloux A, Piquard F, Doutreleau S, et al.: Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 2003, 33:769–778.

    Article  PubMed  CAS  Google Scholar 

  6. Knecht M, Pagel I, Langenickel T, et al.: Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 2002, 71:2701–2712.

    Article  PubMed  CAS  Google Scholar 

  7. Cataliotti A, Chen HH, Redfield MM, Burnett JC Jr: Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin 2006, 2:269–276.

    Article  PubMed  Google Scholar 

  8. Asano K, Dutcher DL, Port JD, et al.: Selective down-regulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 1997, 95:1193–1200.

    PubMed  CAS  Google Scholar 

  9. Leader B, Baca QJ, Golan DE: Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008, 7:21–39.

    Article  PubMed  CAS  Google Scholar 

  10. Cataliotti A, Schirger JA, Martin FL, et al.: Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 2005, 112:836–840.

    Article  PubMed  CAS  Google Scholar 

  11. Yamamoto K, Burnett JC Jr, Redfield MM: Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997, 273:H2406–H2414.

    PubMed  CAS  Google Scholar 

  12. Brunner-La Rocca HP, Kaye DM, Woods RL, et al.: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001, 37:1221–1227.

    Article  PubMed  CAS  Google Scholar 

  13. Mitrovic V, Seferovic PM, Simeunovic D, et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006, 27:2823–2832.

    Article  PubMed  CAS  Google Scholar 

  14. Chen HH, Cataliotti A, Schirger JA, et al.: Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1093–R1097.

    PubMed  CAS  Google Scholar 

  15. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487–1491.

    Article  PubMed  CAS  Google Scholar 

  16. Riter HG, Redfield MM, Burnett JC, Chen HH: Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006, 47:2334–2335.

    Article  PubMed  CAS  Google Scholar 

  17. Witteles RM, Kao D, Christopherson D, et al.: Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2007, 50:1835–1840.

    Article  PubMed  CAS  Google Scholar 

  18. Kurien S, Warfield KT, Wood CM, Miller WL: Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Am J Cardiol 2006, 98:1627–1630.

    Article  PubMed  CAS  Google Scholar 

  19. Arora S, Clarke K, Srinivasan V, Gradman A: Effect of nesiritide on renal function in patients admitted for decompensated heart failure. QJM 2007, 100:699–706.

    Article  PubMed  CAS  Google Scholar 

  20. Wang DJ, Dowling TC, Meadows D, et al.: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004, 110:1620–1625.

    Article  PubMed  CAS  Google Scholar 

  21. Cody RJ, Atlas SA, Laragh JH, et al.: Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986, 78:1362–1374.

    Article  PubMed  CAS  Google Scholar 

  22. Chen HH, Grantham JA, Schirger JA, et al.: Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000, 36:1706–1712.

    Article  PubMed  CAS  Google Scholar 

  23. Chen HH, Sundt TM, Cook DJ, et al.: Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation 2007, 116:1134–1138.

    Article  Google Scholar 

  24. Mentzer RM Jr, Oz MC, Sladen RN, et al.: Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 2007, 49:716–726.

    Article  PubMed  CAS  Google Scholar 

  25. Miller WL, Kurien S, Warfield KT, et al.: Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide. Int J Cardiol 2007 May 4 (Epub ahead of print).

  26. Scriven TA, Burnett JC Jr: Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation 1985, 72:892–897.

    PubMed  CAS  Google Scholar 

  27. Chen HH, Schirger JA, Chau WL, et al.: Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 1999, 100:2443–2448.

    PubMed  CAS  Google Scholar 

  28. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900–1905.

    Article  PubMed  CAS  Google Scholar 

  29. Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE: Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006, 296:1877–1884.

    Article  PubMed  CAS  Google Scholar 

  30. Arora RR, Venkatesh PK, Molnar J: Short and long-term mortality with nesiritide. Am Heart J 2006, 152:1084–1090.

    Article  PubMed  CAS  Google Scholar 

  31. Abraham WT, Adams KF, Fonarow GC, et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57–64.

    Article  PubMed  Google Scholar 

  32. Costanzo MR, Johannes RS, Pine M, et al.: The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 2007, 154:267–277.

    Article  PubMed  CAS  Google Scholar 

  33. Patel JB, Valencik ML, Pritchett AM, et al.: Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2005, 289:H777–H784.

    Article  PubMed  CAS  Google Scholar 

  34. Lainchbury JG, Burnett JC Jr, Meyer D, Redfield MM: Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000, 278:H33–H40.

    PubMed  CAS  Google Scholar 

  35. Cataliotti A, Burnett JC Jr: Natriuretic peptides: novel therapeutic targets in heart failure. J Investig Med 2005, 53:378–384.

    Article  PubMed  CAS  Google Scholar 

  36. Yancy CW, Singh A: Potential applications of outpatient nesiritide in fusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006, 98:226–229.

    Article  PubMed  CAS  Google Scholar 

  37. Yancy CW, Krum H, Massie BM, et al.: Safety and efficacy of outpatient nesiritide in patients with chronic decompensated heart failure: results of the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial. Circulation: Heart Failure (in press).

  38. Burnett JC Jr, Korinek J: The tumultuous journey of nesiritide: past, present and future. Circulation: Heart Failure (in press).

  39. Chen HH, Schirger JA, Cataliotti A, Burnett JC Jr: Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail 2006, 8:681–686.

    Article  PubMed  CAS  Google Scholar 

  40. Chen HH, Huntley BK, Schirger JA, et al.: Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol 2006, 17:2742–2747.

    Article  PubMed  CAS  Google Scholar 

  41. Chen HH, Redfield MM, Nordstrom LJ, et al.: Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004, 10:115–119.

    Article  PubMed  CAS  Google Scholar 

  42. Wang W, Ou Y, Shi Y: AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004, 21:2105–2111.

    Article  PubMed  CAS  Google Scholar 

  43. Gill HS, Prausnitz MR: Coating formulations for microneedles. Pharm Res 2007, 24:1369–1380.

    Article  PubMed  CAS  Google Scholar 

  44. Prescott JH, Lipka S, Baldwin S, et al.: Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol 2006, 24:437–438.

    Article  PubMed  CAS  Google Scholar 

  45. Stevens TL, Burnett JC Jr, Kinoshita M, et al.: A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995, 95:1101–1108.

    Article  PubMed  CAS  Google Scholar 

  46. Joseph R, Pahari S, Hodgson WC, Kini RM: Hypotensive agents from snake venoms. Curr Drug Targets Cardiovasc Haematol Disord 2004, 4:437–459.

    Article  PubMed  CAS  Google Scholar 

  47. Singh G, Kuc RE, Maguire JJ, et al.: Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006, 99:183–190.

    Article  PubMed  CAS  Google Scholar 

  48. Margulies KB, Burnett JC Jr: Visualizing the basis for paracrine natriuretic peptide signaling in human heart. Circ Res 2006, 99:113–115.

    Article  PubMed  CAS  Google Scholar 

  49. Chen HH, Lainchbury JG, Burnett JC Jr: Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 2002, 40:1186–1191.

    Article  PubMed  CAS  Google Scholar 

  50. Lainchbury JG, Lisy O, Burnett JC Jr, et al.: Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. Am J Physiol Regul Integr Comp Physiol 2002, 282:R993–R998.

    PubMed  CAS  Google Scholar 

  51. Lisy O, Lainchbury JG, Leskinen H, Burnett JC Jr: Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 2001, 37:1089–1094.

    PubMed  CAS  Google Scholar 

  52. Wei CM, Kim CH, Miller VM, Burnett JC Jr: Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993, 92:2048–2052.

    Article  PubMed  CAS  Google Scholar 

  53. Lisy O, Huntley BK, McCormick DJ, et al.: Design, synthesis and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2003 (in press).

  54. Martin FL, Stevens TL, Cataliotti A, et al.: Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 2005, 67:1723–1730.

    Article  PubMed  CAS  Google Scholar 

  55. Rouleau JL, Pfeffer MA, Stewart DJ, et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000, 356:615–620.

    Article  PubMed  CAS  Google Scholar 

  56. Guazzi M, Samaja M, Arena R, et al.: Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007, 50:2136–2144.

    Article  PubMed  CAS  Google Scholar 

  57. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr: Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002, 105:999–1003.

    Article  PubMed  CAS  Google Scholar 

  58. Boerrigter G, Costello-Boerrigter LC, Lapp H, et al.: Beneficial actions of co-targeting particulate and soluble guanylate cyclase dependent cGMP pools in experimental heart failure [abstract 2494]. Circulation 2007, 116:II–550.

    Google Scholar 

  59. Forfia PR, Lee M, Tunin RS, et al.: Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007, 49:1079–1088.

    Article  PubMed  CAS  Google Scholar 

  60. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al.: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004, 109:1680–1685.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, 55905, USA

    Josef Korinek

Authors
  1. Josef Korinek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guido Boerrigter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Selma F. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John C. Burnett Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josef Korinek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korinek, J., Boerrigter, G., Mohammed, S.F. et al. Insights into natriuretic peptides in heart failure: An update. Curr Heart Fail Rep 5, 97–104 (2008). https://doi.org/10.1007/s11897-008-0016-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-008-0016-y

Keywords

Search

Navigation